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http://dx.doi.org/1with low-density lipoprotein cholesterol (LDL-C) levels ‡100 and £160 mg/dl while treated
with atorvastatin 10 mg/day entered a multicenter, randomized, double-blind, active-
controlled, clinical trial using two 6-week study periods. Period I compared the efﬁcacy/safety
of (1) adding ezetimibe 10 mg (ezetimibe) to stable atorvastatin 10 mg, (2) doubling ator-
vastatin to 20 mg, or (3) switching to rosuvastatin 10 mg. Subjects in the latter 2 groups who
persisted with elevated LDL-C levels (‡100 and £160 mg/dl) after period I, entered period II;
subjects on atorvastatin 20 mg had ezetimibe added to their atorvastatin 20 mg, or uptitrated
their atorvastatin to 40mg; subjects on rosuvastatin 10mg switched to atorvastatin 20mgplus
ezetimibe or uptitrated their rosuvastatin to 20 mg. Some subjects on atorvastatin 10 mg plus
ezetimibe continued the same treatment into period II. At the end of period I, ezetimibe plus
atorvastatin 10mg reducedLDL-C signiﬁcantlymore than atorvastatin 20mg or rosuvastatin
10mg (22.2% vs 9.5% or 13.0%, respectively, p <0.001). At the end of period II, ezetimibe plus
atorvastatin 20 mg reduced LDL-C signiﬁcantly more than atorvastatin 40 mg (17.4% vs
6.9%, p <0.001); switching from rosuvastatin 10 mg to ezetimibe plus atorvastatin 20 mg
reduced LDL-C signiﬁcantly more than uptitrating to rosuvastatin 20 mg (17.1% vs 7.5%,
p <0.001). Relative to comparative treatments, ezetimibe added to atorvastatin 10 mg
(period I) or atorvastatin 20 mg (period II) produced signiﬁcantly greater percent attainment
of LDL-C targets <100 or <70 mg/dl, and signiﬁcantly greater percent reductions in total
cholesterol, nonehigh-density lipoprotein cholesterol, most lipid and lipoprotein ratios, and
apolipoprotein B (except ezetimibe plus atorvastatin 20 vs atorvastatin 40 mg). Reports of
adverse experiences were generally similar among groups. In conclusion, treatment of
hypercholesterolemic subjects at high cardiovascular risk with ezetimibe added to atorvas-
tatin 10 or 20 mg produced signiﬁcantly greater improvements in key lipid parameters and
signiﬁcantly greater attainment of LDL-C treatment targets than doubling atorvastatin or
switching to (or doubling) rosuvastatin at the compared doses.  2013 Elsevier Inc. All
rights reserved. (Am J Cardiol 2013;112:1885e1895)Few studies have used treat-to-target designs that
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0.1016/j.amjcard.2013.08.031including those at high cardiovascular disease (CVD) risk
with intensive low-density lipoprotein cholesterol (LDL-C)
treatment targets. This 2-period study (each 6 weeks)
examined patients at high CVD risk who did not achieve
LDL-C targets while treated with a commonly prescribed
statin at a commonly used dose (atorvastatin 10 mg/day).
The primary objective of period I was to compare the LDL-
C-lowering efﬁcacy of ezetimibe 10 mg add-on to atorvas-
tatin 10 mg versus doubling atorvastatin to 20 mg or
switching to rosuvastatin 10 mg. The main objective of
period II was to examine subjects who did not achieve an
LDL-C target of <100 mg/dl after period I, compare the
LDL-C-lowering efﬁcacy of adding ezetimibe 10 mg to
atorvastatin 20 mg versus doubling the atorvastatin dose
from 20 mg (period I) to 40 mg, and compare switching
from rosuvastatin 10 mg (period I) to ezetimibe 10 mg plus
atorvastatin 20 mg versus doubling rosuvastatin to 20 mg.
Finally, this study evaluated these sequential treatment
options with regard to achievement of LDL-C treatment
targets of <100 or <70 mg/dl, consistent with Nationalwww.ajconline.org
Figure 1. Study design. Atorva ¼ atorvastatin; EZ ¼ ezetimibe; Rosuva ¼ rosuvastatin.
1886 The American Journal of Cardiology (www.ajconline.org)Cholesterol Education Program, Adult Treatment Panel III
and European Society of Cardiology/European Atheroscle-
rosis Society guidelines.1,2
Methods
This clinical trial entitled A Randomized, Double-Blind,
Active-Controlled, Multicenter Study of Patients with
Primary Hypercholesterolemia and High Cardiovascular
Risk Who Are Not Adequately Controlled with Atorvastatin
10 mg: A Comparison of the Efﬁcacy and Safety of
Switching to Coadministration Ezetimibe and Atorvastatin
Versus Doubling the Dose of Atorvastatin or Switching to
Rosuvastatin (PACE), was conducted from September 29,
2010 to October 17, 2012 (study MK653C-162, http://
clinicaltrials.gov, identiﬁer NCT01154036) and included
subjects evaluated from 296 research sites across 29 coun-
tries (Argentina [18], Belgium [2], Bulgaria [11], Canada
[15], Chile [7], Columbia [5], Croatia [4], Czech Republic
[19], Denmark [5], Estonia [4], Finland [5], France [7],
Germany [9], Hungary [13], Israel [14], Italy [8], Lithuania
[8], the Netherlands [4], Norway [4], Poland [14], Portugal
[4], Romania [18], Slovakia [12], Slovenia [3], Spain [11],
Sweden [6], Turkey [8], the United Kingdom [12], and the
United States [46]). The study was conducted in accordance
with principles of the ICH Good Clinical Practice and all
local and/or national regulations and directives. The
appropriate institutional review boards approved the
protocol, and all subjects documented their agreement to
participate by written informed consent.
Subjects included in the present study were men and
women of nonchildbearing potential and aged 18 and<80 years with primary hypercholesterolemia. Subjects were
required to be at high CVD risk and meet prespeciﬁed lipid
entry criteria. The high CVD risk study entry criteria included
subjects without CVD who had type 2 diabetes mellitus or
2 CVD risk factors and a 10-year risk for coronary heart
disease >20% (as determined by the Framingham risk
calculation) or subjects with known CVD, including patients
with established coronary and other atherosclerotic vascular
diseases.2e4 The lipid study entry criteria included subjects
naive to lipid-lowering therapy (never treated or no therapy
for6 weeks before the prescreen visit) with an LDL-C level
in the predetermined range of 166 to 190 mg/dl or subjects on
a stable dose of statin, ezetimibe, or statin plus ezetimibe
having LDL-C-lowering efﬁcacy equivalent to or less than
atorvastatin 10 mg and with historic lipid values within
a range that might reasonably meet randomization lipid
criteria (described later).
Main exclusion criteria included alanine aminotransferase
or aspartate aminotransferase levels >2 the upper limit of
normal (ULN); creatine kinase >3 the ULN; a history of
signiﬁcant myopathy or rhabdomyolysis with any statin or
ezetimibe; hypersensitivity or intolerance to ezetimibe, ator-
vastatin, rosuvastatin, or any component of these medications;
congestive heart failure (NewYork Heart Association class III
or IV); previousmyocardial infarction, coronary artery bypass
surgery, angioplasty, or acute coronary syndrome within
3 months before screening; uncontrolled cardiac arrhythmias
or recent signiﬁcant changes on an electrocardiogram within
6 months before screening; homozygous familial hypercho-
lesterolemia or LDL-C apheresis; partial ileal bypass, gastric
bypass, or other signiﬁcant intestinal malabsorption; uncon-
trolled hypertension; poorly controlled type 1 or 2 diabetes
Figure 2. Participant distribution. Atorva ¼ atorvastatin; EZ ¼ ezetimibe; FAS ¼ full analysis set (includes all randomized patients with baseline and at least 1
valid postbaseline evaluation); Rosuva ¼ rosuvastatin.
Preventive Cardiology/Ezetimibe Add-on to Atorvastatin 1887mellitus (deﬁned by HbA1c  8.5%); estimated glomerular
ﬁltration rate <30 ml/min/1.73 m2 based on the 4-variable
Modiﬁcation of Diet in Renal Disease equation, nephrotic
syndrome, or other clinically signiﬁcant renal disease; active
liver disease; uncontrolled endocrine or metabolic disease
known to inﬂuence serum lipids or lipoproteins; disorders of
the hematologic, digestive, or central nervous systems
including cerebrovascular disease (e.g., stroke, transient
ischemic attack) and degenerative disease that would limit
study evaluation or participation.
After study entry, lipid-altering drugenaïve subjects were
administered open-label atorvastatin 10 mg/day. For subjects
previously treated with lipid-altering drugs, these lipid-
altering drugs were discontinued, and the subjects were
switched to open-label atorvastatin 10 mg/day. After 5 weeks
of open-label atorvastatin 10 mg/day, subjects were required
to meet a second set of randomization entry criteria which
included LDL-C levels 100 and 160 mg/dl and triglyc-
eride levels400 mg/dl. Subjects meeting these criteria were
randomized to 1 of 6 blinded treatment sequences ina 3:1:8:8:16:16 ratio based on sample size assumptions (see
later), which determined treatment in period I (ﬁrst 6 weeks)
and period II (second 6 weeks) of the study (Figure 1).
Treatment during period I included (1) adding ezetimibe
10 mg to stable atorvastatin 10 mg therapy, (2) doubling
atorvastatin to 20 mg, or (3) switching to rosuvastatin 10 mg.
Subjects in the latter 2 groups who persisted with LDL-C
levels 100 and 160 mg/dl at the end of period I entered
period II; subjects on atorvastatin 20 mg received atorvastatin
20 mg plus ezetimibe 10 mg or atorvastatin uptitrated to
40 mg; those on rosuvastatin 10 mg were switched to ator-
vastatin 20 mg plus ezetimibe 10 mg or uptitrated to rosu-
vastatin 20 mg. Approximately 25% of those receiving
atorvastatin 10 mg plus ezetimibe during period I continued
into period II irrespective of LDL-C levels to maintain study
blinding. Randomization was performed using a central
interactive voice response system. All study personnel,
including investigators, study site personnel, patients, moni-
tors, and central laboratory personnel, remained blinded to
treatment allocation throughout the study; the ﬁnal database
Table 1
Baseline characteristics (all randomized subjects)
Characteristic Period I Period II
E10 þ A10
(n ¼ 120)
A20
(n ¼ 483)
R10
(n ¼ 944)
E10 þ A10/
E10 þ A10
(n ¼ 28)
A20/
E10 þ A20
(n ¼ 124)
A20/
A40
(n ¼ 126)
R10/
E10 þ A20
(n ¼ 234)
R10/
R20
(n ¼ 206)
Men 49 (40.8) 230 (47.6) 455 (48.2) 14 (50.0) 69 (55.6) 63 (50.0) 111 (47.4) 107 (51.9)
Women 71 (59.2) 253 (52.4) 489 (51.8) 14 (50.0) 55 (44.4) 63 (50.0) 123 (52.6) 99 (48.1)
Age (yrs) 60.4  9.4 59.6  10.2 59.9  9.7 61.9  8.7 59.6  10.9 58.2  10.9 59.1  10.2 57.6  10.1
Race
American Indian/
Alaska Native
1 (0.8) 1 (0.2) 0 0 0 1 (0.8) 0 0
Asian 0 0 0 0 0 0 0 0
Black 4 (3.3) 11 (2.3) 28 (3.0) 2 (7.1) 3 (2.4) 3 (2.4) 9 (3.8) 8 (3.9)
Multiracial 2 (1.7) 6 (1.2) 18 (1.9) 0 1 (0.8) 0 3 (1.3) 2 (1.0)
White 113 (94.2) 465 (96.3) 897 (95.0) 26 (92.9) 120 (96.8) 122 (96.8) 222 (94.9) 196 (95.1)
Unknown 0 0 1 (0.1) 0 0 0 0 0
Ethnicity
Hispanic or Latino 32 (26.7) 112 (23.2) 228 (24.2) 9 (32.1) 31 (25.0) 32 (25.4) 52 (22.2) 55 (26.7)
Not Hispanic or Latino 88 (73.3) 369 (76.4) 714 (75.6) 19 (67.9) 92 (74.2) 94 (74.6) 182 (77.8) 151 (73.3)
Unknown 0 2 (0.4) 2 (0.2) 0 1 (0.8) 0 0 0
Body mass index (kg/m2) 30.3  5.2 29.6  5.0 29.6  5.0 31.9  5.1 29.1  4.8 29.7  4.4 29.8  5.0 29.0  5.0
Metabolic syndrome* 81 (67.5) 310 (64.2) 620 (65.7) 22 (78.6) 80 (64.5) 80 (63.5) 159 (67.9) 117 (56.8)
CVD†
No 59 (49.2) 245 (50.7) 465 (49.3) 15 (53.6) 61 (49.2) 70 (55.6) 116 (49.6) 105 (51.0)
Yes 61 (50.8) 238 (49.3) 479 (50.7) 13 (46.4) 63 (50.8) 56 (44.4) 118 (50.4) 101 (49.0)
Diabetes mellitus 60 (50.0) 222 (46.0) 451 (47.8) 11 (39.3) 55 (44.4) 57 (45.2) 116 (49.6) 92 (44.7)
Data are presented as n (%) or mean  SD.
A10/20/40 ¼ atorvastatin 10 mg, 20 mg, or 40 mg; E10 ¼ ezetimibe 10 mg; R10/20 ¼ rosuvastatin 10 mg or 20 mg.
* Having 3 of the following 5 characteristics: waist circumference 102 cm for men or 88 cm for women; triglycerides 150 mg/dl; HDL-C <40 mg/dl
in men or <50 mg/dl in women; 130 mm Hg systolic blood pressure, 85 mm Hg diastolic blood pressure, or on antihypertensive drug treatment in a subject
with a history of hypertension; fasting glucose 100 mg/dl or on drug treatment for elevated glucose.
† CVD is deﬁned as the National Cholesterol Education Program-Adult Treatment Panel III and American Heart Association/American College of
Cardiology guideline deﬁnition of “established atherosclerotic vascular disease.”
1888 The American Journal of Cardiology (www.ajconline.org)was not unblinded until medical/scientiﬁc review was per-
formed, protocol violators were identiﬁed, and data were
declared ﬁnal and complete.
The primary efﬁcacy end point variable was the percent
change from treated baseline in LDL-C levels at the end of
period I. Key secondary end point variables included
percent change from treated baseline in LDL-C at the end of
period II; percentage of subjects achieving LDL-C <100 or
<70 mg/dl at the end of periods I and II; percent change
from treated baseline in other lipids, lipoproteins, and high-
sensitivity C-reactive protein (hs-CRP) at the end of periods
I and II; assessment of safety and tolerability.
Primary and secondary efﬁcacy end point variables were
evaluated using the full analysis set population, including all
randomized subjects receiving 1 dose of blinded study
treatment with baseline and 1 postbaseline measurement.
Because normality was rejected (at the alpha ¼ 0.001 level)
for the primary end point of percent change from baseline in
LDL-C levels after period I, the analysis used a prespeciﬁed
2-step multiple imputation method5 followed by a robust
regression approach6,7 that included terms for treatment and
baseline LDL-C. The robust regression provided iteratively
reweighted-least-square means6 and associated p values to
determine within- and between-treatment effects. Evaluation
of the percentage of patients reaching LDL-C targets <100
or <70 mg/dl used a logistic regression model with terms fortreatment and baseline LDL-C categories (3 categories based
on tertiles). Odds ratio estimates and 95% conﬁdence inter-
vals were used to quantify treatment effects. The percent
change from baseline in other lipid and lipoprotein param-
eters (except triglycerides and hs-CRP) was evaluated using
the robust regression approach as described previously. The
percent change from baseline in log-transformed data for
triglycerides and hs-CRP was assessed using a constrained
longitudinal data analysis method because of the non-normal
distribution seen in previous studies.8 As this study design
employed the use of serial treatment assessments, a parallel
gatekeeping testing approach was applied to control the
overall type-I error rate at an a value of 0.05 for comparisons
of percent change from baseline in LDL-C after periods I and
II. For other evaluations, the false discovery rate was
controlled at 5%. Analysis of prespeciﬁed subgroups
provided least squares means and 95% conﬁdence intervals
by ﬁtting an analysis of covariance repeated measure model
with terms for treatment and baseline LDL-C.
For the primary and secondary efﬁcacy end points, with
a sample size of approximately 1,500 patients planned for
randomization, the study was anticipated to have at least
90% power to demonstrate a difference between ezetimibe
coadministered with atorvastatin and the comparative ator-
vastatin or rosuvastatin monotherapy, assuming a drop-out
rate of w8%, a SD of 20% (a-level of 0.045 [period I] or
Table 2
Baseline parameters (all randomized subjects)
Parameter Period I Period II
E10 þ A10
(n¼ 120)*
A20
(n¼ 483)*
R10
(n¼ 944)*
E10þ A10/
E10þ A10
(n¼ 28)*
A20/
E10 þ A20
(n¼ 124)*
A20/
A40
(n¼ 126)*
R10/
E10 þ A20
(n¼ 234)*
R10/
R20
(n ¼ 206)*
LDL-C (mg/dl)† 121  18 120  17 121  18 107  37 119  16 121  21 119  16 120  17
Total cholesterol (mg/dl) 203  25 203  23 205  24 190  46 202  23 203  25 204  24 203  23
Non-HDL-C (mg/dl) 150  25 150  22 152  23 137  42 151  22 151  24 151  21 150  21
Triglycerides (mg/dl)z 127  80 148  75 147  73 139  105 144  79 141  65 150  61 137  73
HDL-C (mg/dl) 53  13 53  12 53  13 53  15 51  12 52  13 53  15 54  13
Apolipoprotein B (mg/dl) 102  20 103  19 104  19 97  21 102  19 103  18 102  18 103  18
Apolipoprotein AI (mg/dl) 148  26 149  24 148  24 144  29 143  24 147  23 147  26 149  25
Total/HDL-C 4.0  0.9 4.0  0.9 4.1  0.9 3.7  1.0 4.2  1.0 4.1  1.0 4.1  1.0 4.0  0.9
LDL-C/HDL-C 2.4  0.7 2.4  0.6 2.4  0.7 2.1  0.8 2.5  0.7 2.5  0.7 2.4  0.7 2.4  0.6
Non-HDL-C/HDL-C 3.0  0.9 3.0  0.9 3.1  0.9 2.7  1.0 3.2  1.0 3.1  1.0 3.1  1.0 3.0  0.9
Apolipoprotein B/
apolipoprotein AI
0.7  0.2 0.7  0.2 0.7  0.2 0.7  0.2 0.7  0.2 0.7  0.2 0.7  0.2 0.7  0.2
Hs-CRP (mg/L)z 1.9  3.0 2.2  3.0 2.2  3.1 2.0  4.7 2.1  3.0 2.2  3.0 1.9  3.1 2.0  2.8
Data are presented as mean  SD.
Baseline values refer to values measured at randomization (after atorvastatin 10 mg run-in) for period I and values measured at the end of period I for period II.
A10/20/40 ¼ atorvastatin 10 mg, 20 mg, or 40 mg; E10 ¼ ezetimibe 10 mg; R10/20 ¼ rosuvastatin 10 mg or 20 mg.
* Number of all randomized patients evaluated (may vary slightly within each parameter).
† LDL-C was calculated using Friedewald method when triglycerides were <350 mg/dl (3.95 mmol/L) and beta quantiﬁcation ultracentrifugation when
triglycerides were 350 mg/dl.
zMedian  robust SD (SD calculated as interquartile range/1.075, in which the interquartile range is the third quartile minus the ﬁrst quartile.
Preventive Cardiology/Ezetimibe Add-on to Atorvastatin 18890.050 [period II], 2 sided), and an anticipated number of
patients not adequately controlled on atorvastatin 20 mg/day
(50%) or rosuvastatin 10 mg/day (40%) after period I. These
sample size assumptions account for the differences in n
values planned for the various treatment arms.
Safety was evaluated using the all-patients-as-treated
population, including all randomized subjects who received
1 dose of study treatment. Prespeciﬁed safety end points
of special interest for this study were subject to inferential
testing, with p values and 95% conﬁdence intervals deter-
mined for between-group comparisons using a stratiﬁed
Miettinen and Nurminen method.9 Conﬁdence intervals
(95%) for between-group differences were provided for
adverse experience (AE) categories including 1 AE,
serious AEs, drug-related AEs, serious drug-related AEs,
and discontinuations due to an AE. Assessment of drug
causality was determined by the investigator during blinded
study treatment, using the criteria of deﬁnitely, probably,
possibly, probably not, and deﬁnitely not related to study
drug. An AE was deﬁned as “drug related” if the investi-
gator reported the AE as being possibly, probably, or deﬁ-
nitely due to study drug.
Results
Of the 1,547 patients randomized, 1,460 (94%)
completed period I. Afterward, 718 subjects with LDL-C
levels high enough to be eligible to participate proceeded to
period II. Of these, 689 (96%) completed period II
(Figure 2). Study subject discontinuations were 5.6% during
period I (range, 2.5%e5.9%) and 4.0% during period II
(range, 2.9%e6.5%). Baseline characteristics (Table 1) and
lipid and lipoprotein levels (Table 2) were generally similar
across treatment regimens within each period. Patientsrandomized to period I had a mean age of 60 years, 53%
were women, 95% were white, 50% had CVD, and 47% had
diabetes mellitus (0.4% with type 1, 32.4% with type 2, and
14.6% with unknown type). The overall mean baseline
LDL-C level wasw120 mg/dl. Baseline characteristics and
lipid and lipoprotein levels for uncontrolled patients who
continued into period II were similar to those for patients in
period I. Overall, mean compliance at the >95% level of the
prescribed dose was 94% during atorvastatin 10 mg run-in,
91% during period I, and 92% during period II.
For patients with LDL-C levels 100 and 160 mg/dl
after atorvastatin 10 mg run-in, the addition of ezetimibe
to atorvastatin 10 mg produced a signiﬁcantly greater
reduction in LDL-C than doubling the atorvastatin dose
to 20 mg or switching to rosuvastatin 10 mg (Table 3).
Furthermore, the addition of ezetimibe to atorvastatin 10 mg
produced signiﬁcantly greater attainment of LDL-C <100
or<70mg/dl (Figure 3) and signiﬁcantly greater reductions in
total cholesterol, nonehigh-density lipoprotein cholesterol
(HDL-C), apolipoprotein B, and LDL-C/HDL-C, total/
HDL-C, and non-HDL-C/HDL-C ratios (Table 3) than ator-
vastatin 20 mg or rosuvastatin 10 mg. The change from
baseline in HDL-C, triglycerides, apolipoprotein AI, and hs-
CRP were similar among treatments (Table 3). Treatment
effects were similar for percent change from baseline in
LDL-C across all prespeciﬁed subgroups of age, gender, race,
and diabetic status (Figure 4).
For patients who persisted with LDL-C levels 100 and
160 mg/dl after an additional 6 weeks on atorvastatin
20 mg or rosuvastatin 10 mg (which followed the atorvas-
tatin 10 mg run-in), the addition of ezetimibe to atorvastatin
20 mg produced signiﬁcantly greater reductions in LDL-C
and signiﬁcantly greater attainment of LDL-C <100 or
<70 mg/dl than uptitration of atorvastatin to 40 mg
Table 3
Percent change from treated baseline in assessed parameters (full analysis set population)
Parameter Period I Period II
Percent Change from Baseline† Treatment Difference Percent Change from Baseline† Treatment Difference
E10 þ A10
(n ¼ 120)z
A20
(n¼ 480)z
R10
(n¼ 939)z
E10þ A10
vs A20
E10 þ A10
vs R10
A20/ R10/ E10þ A20
vs A40
E10 þ A20
vs R20
E10þ A20
(n¼ 124)z
A40
(n ¼ 124)z
E10þ A20
(n¼ 231)z
R20
(n¼ 205)z
LDL-C 22.2 9.5 13.0 12.7*** 9.1*** 17.4 6.9 17.1 7.5 10.5*** 9.5***
Total cholesterol 13.5 6.4 7.7 7.1*** 5.8*** 10.7 3.8 11.8 4.5 6.8*** 7.4***
Non-HDL-C 18.3 8.1 10.6 10.1*** 7.6*** 15.1 5.8 16.2 6.4 9.3*** 9.8***
HDL-C 0.6 1.1 1.1 1.7 0.6 0.7 1.7 0.1 0.8 1.0 0.7
Triglyceridesx 6.0 3.9 1.1 2.1 4.9 5.9 3.1 10.2 3.2 2.8 7.1*
Apolipoprotein B 11.3 6.0 6.9 5.3** 4.3* 9.8 5.4 11.9 4.1 4.3 7.7***
Apolipoprotein AI 0.2 1.4 1.0 1.6 0.9 1.2 0.7 0.0 1.0 0.5 1.0
LDL-C/HDL-C 21.7 8.0 13.9 13.7*** 7.8*** 19.0 8.7 16.5 8.2 10.4*** 8.3***
Total/HDL-C 13.5 5.5 8.7 8.1*** 4.8** 12.4 5.5 11.3 4.9 6.9*** 6.4***
Non-HDL-C/
HDL-C
17.6 7.0 11.4 10.6*** 6.2** 16.7 7.3 15.1 6.7 9.3*** 8.4***
Apolipoprotein B/
apolipoprotein AI
11.5 5.3 8.0 6.3*** 3.5 11.3 5.5 11.5 5.4 5.8* 6.1**
Hs-CRP (mg/L)x 10.5 6.6 9.0 3.9 1.5 19.5 6.4 10.9 0.7 13.1 11.6
A10/20/40 ¼ atorvastatin 10 mg, 20 mg, or 40 mg; E10 ¼ ezetimibe 10 mg; R10/20 ¼ rosuvastatin 10 mg or 20 mg.
*p <0.05; **p <0.01; ***p <0.001.
† Iteratively reweighted-least squares means (all values except triglycerides and hs-CRP), which are M-estimates based on the method by Huber6; 95%
conﬁdence interval and p value were obtained from ﬁtting a robust regression model with terms for treatment and baseline, after imputing missing values (based
on the method by Rubin5).
z n ¼ Number of all randomized patients evaluated (may vary slightly within each parameter). Includes patients who may only have either a baseline or an
end point observation and those who have both.
x Least squares means based on analysis of log-transformed data, using a constrained longitudinal data analysis model with the log-transformed baseline and
log-transformed postbaseline measurements in the response vector and with ﬁxed effects for treatment, time, and the interaction of time by treatment.
1890 The American Journal of Cardiology (www.ajconline.org)(Table 3, Figure 3). Switching from rosuvastatin 10 mg to
ezetimibe plus atorvastatin 20 mg produced signiﬁcantly
greater reductions in LDL-C and attainment of LDL-C
<100 or <70 mg/dl than uptitration of rosuvastatin to 20 mg
(Table 3, Figure 3). The addition of ezetimibe to atorvastatin
20 mg also produced signiﬁcantly greater reductions in total
cholesterol, non-HDL-C, and all measured lipid and lipo-
protein ratios than either atorvastatin 40 mg or rosuvastatin
20 mg (Table 3). The change from treated baseline in
apolipoprotein B and triglycerides with ezetimibe plus
atorvastatin 20 mg was signiﬁcantly greater than rosuvas-
tatin 20 mg but similar to atorvastatin 40 mg. No signiﬁcant
between-treatment differences were seen for change from
treated baseline in HDL-C, apolipoprotein AI, or hs-CRP.
Treatment effects were similar for percent change from
baseline in LDL-C across prespeciﬁed subgroup categories
of age, gender, race, and diabetic status (Figure 4).
Ezetimibe plus atorvastatin (10 mg or 20 mg), atorvas-
tatin monotherapy (10 mg, 20 mg, or 40 mg), and rosu-
vastatin monotherapy (10 mg or 20 mg) were generally well
tolerated during this 18-week study (Table 4). Overall, at
least 1 AE occurred in 12.6% of patients during period I and
11.1% of patients during period II. No patient in any
treatment group experienced a serious drug-related AE. No
meaningful treatment differences were observed in the
percentage of patients who experienced any AE, any drug-
related AE, any serious AE, or who discontinued study drug
because of an AE.Comparisons of treatment regimens during period I
showed a similar incidence of 1 AE, drug-related AEs, and
serious AEs (Table 4). For period II, the incidence of 1
AE, drug-related AEs, and serious AEs were similar for
patients who received ezetimibe added to atorvastatin 20 mg
versus atorvastatin doubling to 40 mg. Comparing patients
switching from rosuvastatin 10 mg (period I) to ezetimibe
plus atorvastatin 20 mg versus rosuvastatin doubling to
20 mg, the incidence of drug-related and serious AEs were
similar, whereas a numerically greater incidence of 1 AE
was seen with ezetimibe plus atorvastatin 20 mg (Table 4).
This difference was associated with a greater number of
musculoskeletal and connective tissue disorder events, none
of which were myopathy (8 patients [3.5%] vs 1 patient
[0.5%]). No speciﬁc AE was experienced by >3 patients
within any treatment group, and individual AEs were not
indicative of a pattern suggesting a clinically meaningful
difference. Details of investigator-reported, drug-related
AEs occurring during period I (43 patients total) and period
II (16 patients total) are listed in Table 4.
The incidence of prespeciﬁed AEs of special interest was
low, with no signiﬁcant difference seen among the groups
(Table 4). The most frequently reported AE of special
interest during period I and II was gastrointestinal related.
No patient in any treatment group experienced hepatitis-
related or gall bladdererelated AEs or met the Hy’s law
criteria for potential drug-induced liver injury.10 No subject
experienced postbaseline creatine kinase elevations 10
Figure 3. (A) Percent attainment of prespeciﬁed LDL-C target after 6 weeks—period I. †Ratio of the predictive odds of achieving LDL-C level on E10 þ A10
versus either A20 or R10. *p<0.01; **p<0.001. (B) Percent attainment of prespeciﬁed LDL-C target after 6 weeks—period II. †Ratio of the predictive odds of
achieving LDL-C level on E10 þ A20 versus either A40 or R20. *p <0.01; **p <0.001. A10/20/40 ¼ atorvastatin 10 mg, 20 mg, or 40 mg; E10 ¼ ezetimibe
10 mg; R10/20 ¼ rosuvastatin 10 mg or 20 mg.
Preventive Cardiology/Ezetimibe Add-on to Atorvastatin 1891the ULN with or without associated muscle symptoms
during period I or II.
A total of 4 patients experienced consecutive alanine
aminotransferase or aspartate aminotransferase values 3
the ULN during period I or II. During period I, 2 patients
receiving rosuvastatin 10 mg treatment experienced
consecutive elevations in alanine aminotransferase 3 the
ULN (mild intensity) during the last week of treatment. One
of the 2 enzyme elevations was reported as related to study
drug, and both patients discontinued treatment and withdrew
from the study. During period II, 2 patients experienced
elevated liver enzymes. One patient in the atorvastatin
20 mg uptitrated to atorvastatin 40 mg group had an
elevated alanine aminotransferase result 3 the ULN,
which was considered of mild intensity and not related to
study drug. A second patient who switched from rosuvas-
tatin 10 mg in period I to ezetimibe 10 mg plus atorvastatin20 mg in period II experienced consecutive elevations of
alanine aminotransferase and aspartate aminotransferase
10 the ULN, which were reported by the investigator as
AEs of moderate severity and not considered to be related to
study medication. AEs experienced by both patients
occurred at the end of period II, and both patients completed
the study without interruption or discontinuation of study
drug.Discussion
This clinical trial examined various lipid treatment
options in patients at high CVD risk who did not achieve
LDL-C treatment targets during 2 treatment periods. One
unique aspect of the study was its “real-life” study design.
The study began by requiring initial therapy with atorvas-
tatin 10 mg/day as run-in before randomization. This reﬂects
Table 4
Summary of safety data (all patients as treated)
Adverse Experience* Period I Period II
Number (%) of Events Difference in % of Events Number (%) of Events) Difference in % of Events
E10 + A10
(n ¼ 120)*
A20
(n ¼ 480)*
R10
(n ¼ 939)*
E10 + A10 vs A20,
Mean (95% CI)†
p† E10 + A10 vs R10,
Mean (95% CI)†
p† E10 + A10
Y
E10 + A10
(n ¼ 28)*
E10 + A20 vs A40,
Mean (95% CI)†
p† E10 + A20 vs R20,
Mean (95% CI)†
p†
E10 + A20
(n ¼ 124)*
A40
(n ¼ 124)*
E10 + A20
(n ¼ 231)*
R20
(n ¼ 205)*
All patients
1 AE 9 (7.5) 57 (11.9) 128 (13.6) 4.4 (9.2, 2.2) 6.1 (10.4, 0.3) 1 (3.6) 11 (8.9) 13 (10.5) 36 (15.6) 18 (8.8) 1.6 (9.4, 6.0) 6.8 (0.6, 13.0)
Drug relatedz 1 (0.8) 15 (3.1) 27 (2.9) 2.3 (4.5, 1.6) 2.0 (3.6, 1.7) 1 (3.6) 2 (1.6) 3 (2.4) 8 (3.5) 2 (1.0) 0.8 (5.5, 3.6) 2.5 (0.4, 5.8)
Serious 0 3 (0.6) 10 (1.1) 0.6 (0.8, 2.5) 1.1 (1.9, 2.0) 0 2 (1.6) 2 (1.6) 5 (2.2) 1 (0.5) 0.0 (4.3, 4.3) 1.7 (0.7, 4.5)
Serious drug relatedz 0 0 0 0.0 (0.8, 3.1) 0.0 (0.4, 3.1) 0 0 0 0 0 0.0 (3.0, 3.0) 0.0 (1.8, 1.6)
Discontinuationsx 1 (0.8) 9 (1.9) 11 (1.2) 1.0 (2.9, 2.8) 0.3 (1.5, 3.4) 0 1 (0.8) 1 (0.8) 1 (0.4) 1 (0.5) 0.0 (3.7, 3.7) 0.1 (2.3, 2.0)
Deaths 0 0 2 (0.2) 0 0 0 1 (0.4) 0
Prespeciﬁed AEsk
Alanine aminotransferase 3  ULN{ 0 0 2 (0.2) 0 (0.8, 3.1) >0.999 0.2 (0.8, 2.9) 0.613 0 0 1 (0.8) 1 (0.4) 0 0.8 (4.4, 2.2) 0.317 0.4 (1.4, 2.4) 0.346
Alanine aminotransferase 5  ULN 0 0 1 (0.1) 0 (0.8, 3.1) >0.999 0.1 (0.6, 3.0) 0.721 0 0 0 1 (0.4) 0 0.0 (3.0, 3.0) >0.999 0.4 (1.4, 2.4) 0.346
Alanine aminotransferase 10  ULN 0 0 1 (0.1) 0 (0.8, 3.1) >0.999 0.1 (0.6, 3.0) 0.721 0 0 0 1 (0.4) 0 0.0 (3.0, 3.0) >0.999 0.4 (1.4, 2.4) 0.346
Aspartate aminotransferase 3  ULN{ 0 0 0 0 (0.8, 3.1) >0.999 0.0 (0.4, 3.1) >0.999 0 0 0 1 (0.4) 0 0.0 (3.0, 3.0) >0.999 0.4 (1.4, 2.4) 0.346
Aspartate aminotransferase 5  ULN 0 0 0 0 (0.8, 3.1) >0.999 0.0 (0.4, 3.1) >0.999 0 0 0 1 (0.4) 0 0.0 (3.0, 3.0) >0.999 0.4 (1.4, 2.4) 0.346
Aspartate aminotransferase 10  ULN 0 0 0 0 (0.8, 3.1) >0.999 0.0 (0.4, 3.1) >0.999 0 0 0 1 (0.4) 0 0.0 (3.0, 3.0) >0.999 0.4 (1.4, 2.4) 0.346
Alanine aminotransferase and/or
aspartate aminotransferase 3  ULN{
0 0 2 (0.2) 0 (0.8, 3.1) >0.999 0.2 (0.8, 2.9) 0.613 0 0 1 (0.8) 1 (0.4) 0 0.8 (4.4, 2.2) 0.317 0.4 (1.4, 2.4) 0.346
Alanine aminotransferase and/or
aspartate aminotransferase 5  ULN
0 0 1 (0.1) 0 (0.8, 3.1) >0.999 0.1 (0.6, 3.0) 0.721 0 0 0 1 (0.4) 0 0.0 (3.0, 3.0) >0.999 0.4 (1.4, 2.4) 0.346
Alanine aminotransferase and/or
aspartate aminotransferase 10  ULN
0 0 1 (0.1) 0 (0.8, 3.1) >0.999 0.1 (0.6, 3.0) 0.721 0 0 0 1 (0.4) 0 0.0 (3.0, 3.0) >0.999 0.4 (1.4, 2.4) 0.346
Gastrointestinal-related AE 2 (1.7) 12 (2.5) 19 (2.0) 0.8 (3.1, 3.5) 0.589 0.4 (2.1, 3.9) 0.792 1 (3.6) 2 (1.6) 2 (1.6) 2 (0.9) 2 (1.0) 0.0 (4.3, 4.3) >0.999 0.1 (2.7, 2.2) 0.905
Allergic reaction or rash AE 0 2 (0.4) 8 (0.9) 0.4 (1.5, 2.7) 0.479 0.9 (1.7, 2.3) 0.310 0 0 1 (0.8) 0 0 0.8 (4.4, 2.2) 0.317 0.0 (1.8, 1.6) >0.999
% ¼ (number of patients within the AE category/number of treated patients)  100; A10/20/40 ¼ atorvastatin 10 mg, 20 mg, or 40 mg; E10 ¼ ezetimibe 10 mg; R10/20 ¼ rosuvastatin 10 mg or 20 mg.
* All-patients-as-treated population; all randomized patients who took at least 1 dose of study medication. For laboratory safety (alanine aminotransferase, aspartate aminotransferase, creatine kinase, and potential Hy’s law condition), patients must have taken at least 1 dose of
study medication and have at least 1 postbaseline measurement within 14 days of the last dose of study therapy to be included in the analysis.
† Conﬁdence intervals and p values calculated using the Miettinen and Nurminen method.
z Determined by the investigator to be related to the drug; assessment of drug causality determined using following criteria: deﬁnitely, probably, or possibly related deﬁned as “drug related”; probably not and deﬁnitely not related deﬁned as “not related.” Investigator-reported
nonserious drug-related AEs were reported as follows. period I (43 patients total): 1 patient (0.8%) receiving ezetimibe plus atorvastatin 10 mg (muscle spasms); 15 patients (3.1%) receiving atorvastatin 20 mg (abdominal pain upper in 2, breath odor in 1, constipation in 1, dry
mouth in 2, dyspepsia in 1, nausea in 2, edema peripheral in 1, alanine aminotransferase increase in 1, blood creatine kinase increase in 3, myalgia in 1, emotional disorder in 1, rash pruritic in 1, and urticaria in 2); and 27 patients (2.9%) receiving rosuvastatin 10 mg (abdominal pain
upper in 3, constipation in 1, dyspepsia in 1, nausea in 2, asthenia in 2, rhinitis in 1, alanine aminotransferase increase in 3, aspartate aminotransferase increase in 3, blood creatine kinase increase in 4, gamma glutamyltransferase increase in 2, muscle spasms in 2, musculoskeletal
chest pain in 2, myalgia in 3, dizziness in 1, headache in 4, paresthesia in 1, mood altered in 1, dermatitis allergic in 1, hyperhidrosis in 1, rash pruritic in 1, and pallor in 1). Period II (16 patients total): 1 patient (3.6%) receiving ezetimibe 10 mg plus atorvastatin 10 mg/ ezetimibe
10 mg plus atorvastatin 10 mg (abdominal pain upper), 2 patients (1.6%) receiving atorvastatin 20 mg/ ezetimibe 10 mg plus atorvastatin 20 mg (fatigue in 1 and alanine aminotransferase increase in 1), 3 patients (2.4%) receiving atorvastatin 20 mg/ atorvastatin 40 mg
(abdominal pain upper in 1, alanine aminotransferase increase in 1, aspartate aminotransferase increase in 1, dysgeusia in 1, and headache in 1), 8 patients (3.5%) receiving rosuvastatin 10 mg/ ezetimibe 10 mg plus atorvastatin 20 mg (ﬂatulence in 1, alanine aminotransferase
increase in 1, aspartate aminotransferase increase in 2, blood creatine kinase increase in 1, arthralgia in 1, muscle spasms in 1, musculoskeletal pain in 1, dizziness in 1, and headache in 1), and 2 patients (1.0%) receiving rosuvastatin 10 mg/ rosuvastatin 20 mg (blood creatine
kinase increase in 2).
x Study medication withdrawn.
k Prespeciﬁed AEs of special interest. There were no reports of creatine kinase 10 the ULN, potential Hy’s law (alanine aminotransferase or aspartate aminotransferase elevations >3 the ULN, with serum alkaline phosphatase <2 the ULN and total bilirubin 2 the
ULN), hepatitis-related AEs, or gall bladdererelated AEs.
{ Patients with 2 consecutive measurements of 3 the ULN, a single last measurement of 3 the ULN, or a measurement of 3 the ULN followed by a measurement of <3 the ULN taken >2 days after the last dose of study medication.
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Figure 4. (A) Percent change from treated baseline in LDL-C for prespeciﬁed subgroups after 6 weeks—period I. Treatments were (1) ezetimibe plus ator-
vastatin 10 mg (closed diamonds), (2) atorvastatin 20 mg (open circles), or (3) rosuvastatin 10 mg (open triangles). MetS ¼ subgroup of patients with
metabolic syndrome and no diabetes; Neither ¼ no metabolic syndrome or diabetes; n ¼ number of subjects in each subgroup for ezetimibe plus atorvastatin
10 mg, atorvastatin 20 mg, and rosuvastatin 10 mg, respectively. Between-treatment differences within each subgroup are ezetimibe plus atorvastatin 10 mg
minus atorvastatin 20 mg (open circles) and ezetimibe plus atorvastatin 10 mg minus rosuvastatin 10 mg (open triangles). (B) Percent change from treated
baseline in LDL-C for prespeciﬁed subgroups after 6 weeks—period II. Treatments during periods I and II were (1) atorvastatin 20 mg/ atorvastatin 20 mg
plus ezetimibe (closed diamonds), (2) atorvastatin 20 mg/ atorvastatin 40 mg (open circles), (3) rosuvastatin 10 mg/ atorvastatin 20 mg plus ezetimibe
(open triangles), or (4) rosuvastatin 10 mg / rosuvastatin 20 mg (). n ¼ number of subjects in subgroup for each treatment regimen (1, 2, 3, 4, as
aforementioned). Treatment differences within a subgroup are ezetimibe plus atorvastatin 20 mg minus atorvastatin 40 mg (open circles) and ezetimibe plus
atorvastatin 20 mg minus rosuvastatin 20 mg ().
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1894 The American Journal of Cardiology (www.ajconline.org)the common clinical practice of prescribing a statin (which
is often a generic statin) as the initial pharmacologic therapy
to treat hypercholesterolemia in patients at high CVD risk.
After the 5 week run-in on atorvastatin 10 mg/day, study
subjects who were not at LDL-C treatment target were then
randomized to a number of therapeutic approaches, with
each being illustrative examples of cholesterol-lowering
options often considered for the purpose of achieving
LDL-C treatment targets. The study went yet further in
evaluating treatment options among those who still did not
achieve LDL-C treatment targets, despite initial treatment
with atorvastatin 10 mg/day and subsequent adjustment in
lipid-altering drug therapy. The ﬁndings of this study can be
summarized as follows:
1) Among hypercholesterolemic patients at high CVD
risk treated with atorvastatin 10 mg/day having LDL-
C levels that continued to exceed LDL-C treatment
targets (i.e., 100 and 160 mg/dl), ezetimibe 10 mg
plus atorvastatin 10 mg reduced LDL-C signiﬁcantly
more than doubling atorvastatin from 10 to 20 mg and
signiﬁcantly more than switching atorvastatin 10 mg
to rosuvastatin 10 mg.
2) Among hypercholesterolemic patients at high CVD
risk who had their atorvastatin 10 mg/day doubled to
20 mg/day and who continued to have LDL-C levels
that exceeded treatment targets, ezetimibe 10 mg plus
atorvastatin 20 mg reduced LDL-C signiﬁcantly more
than doubling atorvastatin 20 to 40 mg.
3) Among hypercholesterolemic patients at high CVD
risk who had switched from atorvastatin 10 mg/day to
rosuvastatin 10 mg/day and who continued to have
LDL-C levels that exceeded treatment targets,
switching to ezetimibe 10 mg plus atorvastatin 20 mg
reduced LDL-C signiﬁcantly more than doubling
rosuvastatin from 10 to 20 mg.
Concomitant with greater LDL-C lowering, relative to
comparative treatments, ezetimibe added to atorvastatin
10 mg (period I) or atorvastatin 20 mg (period II) produced
signiﬁcantly greater percent attainment of LDL-C targets of
<100 or <70 mg/dl1,2 and produced signiﬁcantly greater
percent reductions in total cholesterol, non-HDL-C, apoli-
poprotein B (except ezetimibe plus atorvastatin 20 mg vs
atorvastatin 40 mg) and lipid and lipoprotein ratios. These
results are consistent with the comparative effects of adding
ezetimibe to ongoing statins versus statin titration seen in
other studies of moderately high- to high-risk subjects with
inadequately controlled LDL-C during statin therapy.11e13
Previous studies suggest that doubling of the statin dose
typically results in an incremental reduction of 5% to 7%
from untreated baseline.14 This is consistent with the ﬁnd-
ings of the present study, wherein doubling atorvastatin or
rosuvastatin reduced LDL-C by an additional 6.9% to 9.5%.
Switching to a different statin represents a second option for
management of hypercholesterolemia.14,15 In the present
study, switching from atorvastatin 10 mg to rosuvastatin
10 mg resulted in greater LDL-C lowering. Adding ezeti-
mibe to ongoing statin therapy represents yet another ther-
apeutic alternative.16 In the present study, addition of
ezetimibe to ongoing atorvastatin 10 mg during period Ireduced LDL-C by 22%, and adding ezetimibe to atorvas-
tatin 20 mg during period II reduced LDL-C by 17%. Few
clinical trials have evaluated the sequential modiﬁcation of
lipid-altering therapy on LDL-C lowering and attainment of
treatment targets.17 Results from the present trial suggest
that statin doubling and ezetimibe add-on treatment strate-
gies produce incremental LDL-C-lowering for patients with
persistent LDL-C levels 100 mg/dl after 6 weeks of
atorvastatin 10 mg (period I) or after atorvastatin 10 mg
followed by an additional 6 weeks on atorvastatin 20 mg or
rosuvastatin 10 mg (period II).
Study treatment approaches were generally similar with
regard to safety and tolerability and generally consistent
with previous clinical studies of similar duration. Study
limitations include the short duration of the study and
a study population that was mostly white, thus limiting the
generalizability of study results for long-term therapy or
more diverse populations. Additionally, although this trial
evaluated the effect of study medications on lipids and other
parameters, this study was neither designed to evaluate nor
did it evaluate the effect of ezetimibe on CVD outcomes.Acknowledgment: The authors gratefully acknowledge the
contributions of the study investigators and thank Kathleen
Newcomb and Martha Vollmer, employees of Merck & Co.
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